linjc16/ctgov huggingface dataset:
Satiety Effects of the Combination of Egg and Whole Grains

Study Overview
=================
Brief Summary
-----------------
The satiety effects of the combination of protein and fiber within egg and whole grain breakfast meals. High protein with low and high-fiber is hypothesized to be more satiating than low protein, low fiber.

Detailed Description
-----------------
Subjects will consume 3 different breakfast meals. Satiety will be measured by visual analogue scales; food intake will be recorded at subsequent meal as well as 24 hour food log; blood glucose response will be assessed following test meals. Subjects will consume an ad libitum lunch meal 3.5 hours after breakfast meal and food intake will be measured.

Official Title
-----------------
The Effects of the Combination of Egg and Whole Grains on Appetite, Blood Glucose Response and Food Intake

Conditions
-----------------
Food Selection

Intervention / Treatment
-----------------
* Other: Egg refined grain
* Other: Egg Whole Grain
* Other: Cereal Refined grain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy, non-smoking, BMI of 18-27, non-dieting, typically consumes breakfast/lunch Exclusion Criteria: distaste for eggs, vegetarian, current smoker, restrained eating habits, recent weight change, history of significant disease of past medical history, pregnant, lactating irregular menstrual cycle

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Egg refined grain<br>Eggs with white toast | Other: Egg refined grain<br> <br> Other: Egg Whole Grain<br> <br> Other: Cereal Refined grain<br> <br> |
| Active Comparator: Egg whole grain<br>Eggs with whole grain toast | Other: Egg refined grain<br> <br> Other: Egg Whole Grain<br> <br> Other: Cereal Refined grain<br> <br> |
| Active Comparator: Cereal Refined grain<br>rice cereal with white toast | Other: Egg refined grain<br> <br> Other: Egg Whole Grain<br> <br> Other: Cereal Refined grain<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satiety | Measure satiety by visual analog scales (VAS) | 210 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food intake | ab libitum lunch provided to assess food intake variation between treatments | 210 minutes | 
| Blood glucose response | blood glucose response via finger stick following test meals | 180 minutes |
KinectROM Application for Assessing Range of Motion in Upper and Lower Extremity: A Development and Validation Study

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the validity and reliability of KinectROM application for objectively evaluating range of motion (ROM)

Detailed Description
-----------------
The application KinectROM called has been developed for assessing ROM with Kinect controller by our team. So, shoulder, elbow, knee, hip and ankle ROM measurements will be made with universal goniometer and developed KinectROM application.

Official Title
-----------------
KinectROM Application for Assessing Range of Motion in Upper and Lower Extremity: A Development and Validation Study

Conditions
-----------------
Range of Motion

Intervention / Treatment
-----------------
* Device: Assessment of Range of Motion with Kinect Controller


Participation Criteria
=================
Eligibility Criteria
-----------------
inclusion Criteria: -Healthy individuals with 18-40 years Exclusion Criteria: -Have any limited extremity between the ages of 18-40 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Range of motion in upper extremity<br>Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion | Device: Assessment of Range of Motion with Kinect Controller<br>* A ROM measurement method called as KinectROM by us has been developed with Kinect Controller<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Range of Motion | ROM of shoulder, elbow, knee, hip and ankle will be made with universal goniometer and developed Kinect controller based measurement method. | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
range of motion, upper extremity, lower extremity
Epidural and Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
In the present study the investigators test the hypothesis that the epidural anesthesia added on the general anesthesia is able to improve patient's outcome.

Official Title
-----------------
Epidural Analgesia in Cardiac Surgery

Conditions
-----------------
Cardiac Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing cardiac surgery adult (>18y) sternotomy Exclusion Criteria: abnormal coagulation profile antiplatelet medications (other than aspirin) ongoing anticoagulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| epidural<br> | |
| standard<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac surgery, cardiac anesthesia, epidural
Physiological Responses to a Prolonged Cycling Expedition in Older Men

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to test the physiological response to a 2800 km cycling expedition, from Copenhagen, Denmark to Nordkapp, Norway, in a group of older male recreational cyclists.

Official Title
-----------------
Physiological Responses to a Prolonged Cycling Expedition in Older Men

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Behavioral: Cycling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in the cycling expedition Exclusion Criteria: None
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Cycling|Cycling distance of 2880 km in 14 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total daily energy expenditure (Measured using the doubly labeled water technique) | Measured using the doubly labeled water technique | Change from baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak fat oxidation (Measured during incremental submaximal exercise) | Measured during incremental submaximal exercise | Change from baseline |
Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis

Study Overview
=================
Brief Summary
-----------------
In this research study we want to learn more about the character of neutrophils that are present in the blood of children with sepsis. Sepsis is a severe type of infection, affecting various parts of the body. Neutrophils are a type of white blood cell that are part of the body's immune system. Even though neutrophils are important in getting rid of germs, they also may be harmful to parts of the body by causing injury in organs in patients with sepsis. Neutrophils can change their character in sepsis. Because of this, it is important for doctors to know what kind of neutrophils are in the blood of children with sepsis so that they can work to develop therapies to prevent these cells from being harmful.

Official Title
-----------------
Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis

Conditions
-----------------
Sepsis

Intervention / Treatment
-----------------
* Other: sepsis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patients will be eligible for enrollment as septic patients if they Are < 18 years old Meet the definition of sepsis described in the study design section above. Patients will be eligible for enrollment as control patients if they Are < 18 years old Are scheduled for an elective surgical procedure and need preoperative blood draw or will have an intravenous catheter placed for the purpose of their surgical procedure. Exclusion criteria Patients will be ineligible for enrollment in either control or sepsis group if any of the followings is present or anticipated Congenital cardiac disease On chronic immunosuppressive drugs such as chronic corticosteroid use, or preexisting immunodeficiency diseases

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sepsis<br> | Other: sepsis<br>* patients in the ICU with infection called sepsis<br>|
| Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neutrophil populations | compare gene expression in neutrophils between sepsis patients and non-sepsis patients in pediatric population to report unregulated and down regulated genes | up to 1 month |
Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Study Overview
=================
Brief Summary
-----------------
This study will assess optimal duration of pre-operative treatment with letrozole and to correlate clinical efficacy with appropriate surrogate markers.

Official Title
-----------------
Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Letrozole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Female Breast Cancer patients with primary invasive breast cancer, histologically confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive (Clinical Stage *T2, T3, T4a,b,c, N0, M0) Patients after menopause Tumor measurable by clinical examination, mammography and ultrasound Adequate bone marrow, renal and hepatic function A life expectancy of at least 6 months. Exclusion criteria: Prior treatment with aromatase inhibitors or antiestrogens. Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or hyperthyroidism, Cushing´s Syndrome, Addison´s disease (treated or untreated), Patients with unstable angina, uncontrolled cardiac disease (e.g. Class II or IV New York Heart Association's Functional Classification). Patients with tumors in both breasts, evidence of inflammatory breast cancer or distant metastasis Patients who are eligible for breast conserving surgery. Concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers (BRM's), endocrine therapy (including steroids), bisphosphonate therapy and radiotherapy. Patients who have received HRT will NOT be excluded, provided that HRT is discontinued at least 2 weeks prior to entry into the study. Other protocol defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Letrozole<br> | Drug: Letrozole<br> <br> * Other names: FEM345;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, neoadjuvant treatment, treatment duration, Primary hormone receptor positive, breast cancer in postmenopausal women
The Prevalence of Oral Habits in a Group of Primary School Children in Cairo Governorate

Study Overview
=================
Brief Summary
-----------------
This study is designed to determine the prevalence of oral habits among primary Egyptian school children in Cairo Governorate, Egypt.

Detailed Description
-----------------
This aim of this study is to determine the prevalence of oral habits among primary Egyptian school children in Cairo Governorate, Egypt. PICO: P: Egyptian primary school children of 7 - 10 years old O: Prevalence of oral habits Primary Outcome: Prevalence of Oral Habit; Device of Measurement: Questionnaire; Unit of Measurement: Binary.

Official Title
-----------------
The Prevalence of Oral Habits in a Group of Primary School Children in Cairo Governorate: A Cross-Sectional Study

Conditions
-----------------
Oral Habit

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cooperative children of 7-10 years old Children with no intellectual problems Exclusion Criteria: Children with orthodontic appliances Medically compromised children Children of families who refuse to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Males<br>Primary school Egyptian boys from 7-10 years. | |
| Females<br>Primary school Egyptian girls from 7-10 years. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Oral Habit | Measurement that will be used: Questionnaire | 5 months |
A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill

Study Overview
=================
Brief Summary
-----------------
Corneal damage in critically ill patients is common. There are currently two popular methods of treatment in the UK; hydrogel dressings and lubricating ointment. We propose to randomise patients to have a different treatment for each eye and see which one is more effective.

Detailed Description
-----------------
Microbial keratitis, particularly pseudomonas-related, has been widely reported amongst Intensive therapy unit (ITU) patients and the need for effective eye care in ITU has been recognised for some time. We compare two popular methods of eye care; a hydrogel dressing and lacrilube ointment. Each recruited patient had each eye randomised to different treatments. Daily ophthalmology ward rounds were undertaken to identify any corneal exposure keratopathy. Patients were removed from the trial if one eye developed significant exposure needing treatment.

Official Title
-----------------
Randomised Trial Comparing the Efficacy of Ocular Lubricant (Lacrilube) and Polyacrylamide Hydrogel Dressing (Geliperm) for the Prevention of Exposure Keratopathy in the Critically Ill

Conditions
-----------------
Keratitis

Intervention / Treatment
-----------------
* Other: Hydrogel dressing
* Other: Lacrilube ointment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to Intensive care and expected to stay for more than 2 days Exclusion Criteria: Primary orbital injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Geliperm Hydrogel Dressing | Other: Hydrogel dressing<br>* 3x3cm hydrogel dressing over closed eye<br>|
| Active Comparator: 2<br>Lacrilube ointment | Other: Lacrilube ointment<br>* lubricant put into eye (inferior formix)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of clinically significant corneal exposure |  | throughout length of admission to ITU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eye, keratopathy, exposure, intensive care, ulcer, Corneal
The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

Study Overview
=================
Brief Summary
-----------------
To assess the long-term safety and toleration of eplerenone in the children aged 6 to 16 years with high blood pressure. The study will last at least 1 year and about 140 patients will participate.

Official Title
-----------------
Peds II (Pediatric Eplerenone Development Study II)--An Open Label, Long-Term Study To Evaluate The Safety Of Eplerenone In The Treatment Of Hypertension In Children

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Eplerenone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females aged 6 to 16 years The seated systolic blood pressure greater than or equal to the 95th percentile for age, gender and height, measured on at least 3 separate occasions Exclusion Criteria: K/DOQI classification of stages of chronic kidney disease equal to 4 or 5 Serum or whole blood potassium > 5.5. mEq/L

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Eplerenone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of eplerenone in hypertensive children |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy and pharmacokinetics of eplerenone in hypertensive children |  |  |
A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.

Official Title
-----------------
A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation

Conditions
-----------------
Smoking

Intervention / Treatment
-----------------
* Drug: taranabant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Smoking greater than/equal to 10 cigarettes/day for at least 1 year Laboratory tests that meet the criteria of the study In overall good health as determined by the investigator Exclusion Criteria: Psychiatric diagnoses Certain cancers Patients who use nicotine replacement therapy Patients on a diet regimen

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: taranabant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quitting smoking after 8 weeks of treatment by measuring lab values and expired breath CO levels |  | after 8 weeks of treatment |